言語を選択

latent GDF-8

latent GDF-8 詳細

英語名	Growth/differentiation factor 8	市販薬剤の数	0
治験薬の数	6	ターゲットの別称	MSTN，GDF-8，GDF8，Growth Differentiation Factor 8，MSLHP，Myostatin，Growth/Differentiation Factor 8
研究＆開発段階	NDA/BLA

英語名	Growth/differentiation factor 8
ターゲットの別称	MSTN，GDF-8，GDF8，Growth Differentiation Factor 8，MSLHP，Myostatin，Growth/Differentiation Factor 8
市販薬剤の数	0
治験薬の数	6
研究＆開発段階	NDA/BLA

お問い合わせ

latent GDF-8バックグランド

Growth differentiation factor 8 (GDF8), also known as myostatin, is a unique member of the transforming growth factor-β superfamily that is expressed in human granulosa cells and has important roles in regulating a variety of ovarian functions. GDF8 acts as a negative regulator of skeletal muscle growth and differentiation. In addition to the expression in the musculoskeletal system, GDF8 is also expressed in various tissues, including the reproductive system.

latent GDF-8分子の別称

latent GDF-8

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Talditercept alfa	RO-7239361; BMS-986089; RG-6206; BHV-2000	Phase 3 Clinical	Bristol-Myers Squibb Company	Muscular Dystrophy, Duchenne; Neuromuscular Diseases; Muscular Atrophy, Spinal	詳細
RO-7204239	GYM-329; RO-7204239; RG-6237; RG-70240	Phase 3 Clinical	F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co Ltd	Muscular Dystrophy, Facioscapulohumeral; Muscular Atrophy, Spinal	詳細
Trevogrumab	REGN-1033; REGN1033; SAR-391786; GDF8	Phase 2 Clinical	Regeneron Pharmaceuticals Inc	Myositis, Inclusion Body; Obesity; Sarcopenia	詳細
AAV1-FS344	AAV1-Follistatin; AAV1-FS344	Phase 2 Clinical	Nationwide Children'S Hospital	Becker muscular dystrophy; Myositis, Inclusion Body; Muscular Dystrophy, Duchenne	詳細
KER-065	KER-065; RKER-065	Phase 1 Clinical	Keros Therapeutics Inc	Neuromuscular Diseases; Obesity	詳細
HS135	HS-135	Phase 1 Clinical	35Pharma Inc	Hypertension, Pulmonary; Heart Failure, Diastolic; Pulmonary Arterial Hypertension	詳細